RxDoctor Payments Data

Debra Kelsh

Psychiatry · Kansas City, KSNPI 1083716781

Payments from drug & device makers

What this record shows

That places this record below the midpoint for psychiatry clinicians in KS, where the typical reported total is $192.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$25,208,351in research payments, 2019–2025

Across 191 payments — averaging $131,981 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Azurity Pharmaceuticals, Inc.$7.5M
  • Janssen Research & Development, LLC$7.4M
  • Sage Therapeutics, LLC$4M
  • Immedica Pharma US, Inc.$3.7M
  • Cidara Therapeutics, Inc.$1.1M
  • Astrazeneca UK Limited$670K
  • plus $756K from 3 others

How this compares

$0 in reported general payments places this provider in the 10th percentile of 259 psychiatry providers in Kansas.

See all psychiatry providers in Kansas

Other psychiatry in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →